Adherence, Patient, Atrial Fibrillation
Conditions
Brief summary
The ASTORIA study is a prospective cohort single-armed multicenter observational study that aims to assess adherence to rivaroxaban using a high technological electronical pillbox connected to a phone application in a group of atrial fibrillation patients with indication of long term anticoagulation treatment in routine clinical practice.
Interventions
BEHAVIORALAdherence
Adherence to medication using an electronic pillbox
Sponsors
Pilloxa
Oslo University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Female or male patient with age \> 18 years * Patients with atrial fibrillation * Patients initiated, continued on or switched to rivaroxaban for the indication atrial fibrillation with intended lifelong treatment (CHA2 DS2-VASc score ≥ 1). * The patient must agree to the use of the electronic medication adherence monitoring device, the so-called Pilloxa box and need to have a sufficient understanding of the app and functionality in conjunction with the use of the Pilloxa box. * Signed informed consent * No participation in an investigational program with interventions outside of routine clinical practice * No contra-indications according to the local marketing authorization
Exclusion criteria
* Participation in an investigational program with interventions outside of routine clinical practice * Contra-indications according to the local marketing authorization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of adherence | 2 years | The rate of adherence to rivaroxaban in a group of atrial fibrillation patients using the Pilloxa box will be assessed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Persistence rate | 2 years | Rate of persistence to rivaroxaban in a group of atrial fibrillation patients using the Pilloxa box will be assessed |
| Rates of risk factors | 2 years | Risk factors for non-adherence and non-persistence in these patients will be evaluated |
| Rates of different patient experiences | 2 years | Patient experiences with the Pilloxa box and application will be evaluated using questionnaires and quality intervjues |
Contacts
Primary ContactDan Atar, MD, PhD
Backup ContactMarita Knudsen Pope, MD
Outcome results
None listed